QIAGEN NV Hits Day Low of $33.82 Amid Price Pressure

QIAGEN NV, a small-cap player in the Pharmaceuticals & Biotechnology sector, experienced significant volatility on April 28, 2026, with the stock declining by 10.69% and hitting an intraday low of USD 33.82. This performance starkly contrasts with the S&P 500, which saw a modest decline of 0.49% on the same day. Over the past week, QIAGEN NV has faced a 15.16% drop, while its one-month performance shows a decrease of 12.93%. Year-to-date, the stock has fallen by 28.13%, and its three-year performance reflects a decline of 31.68%. Despite these challenges, the company maintains a low Debt to EBITDA ratio of 0.91, indicating a strong capacity to service its debt. Financial metrics reveal that while QIAGEN NV's operating profit has grown at an annual rate of 5.15% over the last five years, its return on equity stands at 12.51%. The stock is currently trading at a discount compared to its peers, with a price-to-earnings ratio of 18.00. As the company navigates these market dynamics, its performance continues to be closely monitored.